Inovio Pharmaceuticals, Inc. (INO) Earnings History
Annual and quarterly earnings data from 1999 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -51616.9% | -49254.3% |
| 2023 | 100.0% | -17300.3% | -16239.9% |
| 2022 | 100.0% | -2607.4% | -2726.7% |
| 2021 | 100.0% | -16972.3% | -17109.9% |
| 2020 | 100.0% | -1674.2% | -2245.4% |
Download Data
Export INO earnings history in CSV or JSON format
Free sign-in required to download data
Inovio Pharmaceuticals, Inc. (INO) Earnings Overview
As of February 28, 2026, Inovio Pharmaceuticals, Inc. (INO) reported trailing twelve-month net income of -$108M, reflecting +0.4% year-over-year growth. The company earned $-2.07 per diluted share over the past four quarters, with a net profit margin of -492.5%.
Looking at the long-term picture, INO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$5M in fiscal 2003.
Inovio Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including BNTX (-$572M net income, -0.2% margin), MRNA (-$3.12B net income, -1.1% margin), SMMT (-$1.08B net income), INO has room to improve margins relative to the peer group. Compare INO vs BNTX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
26 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$107M | +20.6% | -$112M | $-3.95 | -49254.3% | -51616.9% |
| 2023 | -$135M | +51.7% | -$144M | $-6.09 | -16239.9% | -17300.3% |
| 2022 | -$280M | +7.9% | -$268M | $-14.07 | -2726.7% | -2607.4% |
| 2021 | -$304M | -82.5% | -$301M | $-1.42 | -17109.9% | -16972.3% |
| 2020 | -$166M | -39.4% | -$124M | $-1.07 | -2245.4% | -1674.2% |
| 2019 | -$119M | -23.1% | -$111M | $-0.97 | -2902.8% | -2702.1% |
| 2018 | -$97M | -9.9% | -$94M | $-1.05 | -318.1% | -308.7% |
| 2017 | -$88M | -19.6% | -$84M | $-1.08 | -208.9% | -198.1% |
| 2016 | -$74M | -152.6% | -$76M | $-1.01 | -208.5% | -215.5% |
| 2015 | -$29M | +19.2% | -$34M | $-0.43 | -71.9% | -84.5% |
See INO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare INO vs AGIO
See how INO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is INO growing earnings?
INO EPS of $-2.07 reflects slowing growth at +0.4%, below the 5-year CAGR of N/A. TTM net income is $-108M. Expansion rate has moderated.
What are INO's profit margins?
Inovio Pharmaceuticals, Inc. net margin is -492.5%, with operating margin at -516.2%. Below-average margins reflect competitive or cost pressures.
How consistent are INO's earnings?
INO earnings data spans 1999-2024. The current earnings trend is +0.4% YoY. Historical data enables comparison across business cycles.